ERBB2 and breast carcinoma: As a result, the current standard of care for patients with HER2-positive breast cancer in the clinic is trastuzumab in combination with pertuzumab (Perjeta), another anti-HER2 mAb developed by Roche/Genentech, plus paclitaxel [14].